Here are the DEF 14A proxy statements from Innoviva, Inc. (INVA) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow INVA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INVA filings page.
Innoviva, Inc. is asking stockholders to vote at its May 4, 2026 annual meeting on corporate governance, pay, auditors and a major new equity plan. Investors will elect five directors, cast an advisory Say-On-Pay vote and consider ratifying Deloitte & Touche LLP as auditor for 2026.
A key item is approval of the 2026 Equity Incentive Plan, reserving 9,000,000 shares of common stock, about 10% of fully diluted shares as of March 9, 2026, to support future stock-based compensation and contingent grants to executives and employees. The proxy highlights strong 2025 results, including net income of $3.30 per diluted share, roughly $645 million in cash and receivables, over $75 million invested in healthcare opportunities and a new $125 million share repurchase program.